ahlam1399
07-15-2016, 07:15 PM
Valeant psoriasis drug?s suicide risk hard to assess: FDA Staff
(Reuters) - Valeant Pharmaceuticals International Inc's experimental drug to treat the skin disorder psoriasis carries a potential risk of suicide that is challenging to assess due to limited data, according to a preliminary review by the U.S. Food and Drug Administration published on Friday.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=8Cd6qVAoDDE:ugpeYxoYf2g:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=8Cd6qVAoDDE:ugpeYxoYf2g:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=8Cd6qVAoDDE:ugpeYxoYf2g:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=8Cd6qVAoDDE:ugpeYxoYf2g:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=8Cd6qVAoDDE:ugpeYxoYf2g:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/8Cd6qVAoDDE
(Reuters) - Valeant Pharmaceuticals International Inc's experimental drug to treat the skin disorder psoriasis carries a potential risk of suicide that is challenging to assess due to limited data, according to a preliminary review by the U.S. Food and Drug Administration published on Friday.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=8Cd6qVAoDDE:ugpeYxoYf2g:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=8Cd6qVAoDDE:ugpeYxoYf2g:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=8Cd6qVAoDDE:ugpeYxoYf2g:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=8Cd6qVAoDDE:ugpeYxoYf2g:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=8Cd6qVAoDDE:ugpeYxoYf2g:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/8Cd6qVAoDDE